News
Novo Nordisk ousts CEO
Digest more
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Novo Nordisk, the global pharmaceutical leader headquartered in Denmark, has launched a major initiative to combat Thailand’s ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...
Novo Nordisk (NVO, Financials) shares fell nearly 4% after the company said CEO Lars Fruergaard Jrgensen will step down. A ...
Most major stock indexes across the globe moved upwards on a weekly basis, taking support from the uptick in US equities.
Explore more
Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results